Caribou Biosciences

CRBU · NASDAQ

$0.519+$0.055 (+11.85%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $0.464

About CRBU

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 97 full-time employees. The company went IPO on 2021-07-23. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. The company is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.

Employees: 97
Headquarters: Berkeley, California
Listed: Jul 23, 2021
Sector: Health Care
Industry: Biotechnology
Website: cariboubio.com

Leadership

Caribou Biosciences executives
Name	Title	Since	Age
Andrew Guggenhime	—	—	57
Rachel Haurwitz	—	2021	39
Sriram Ryali	—	—	44
Tim Kelly	—	—	56
Steven Kanner	—	—	66
Tina Albertson	—	—	52
Ruhi Khan	—	—	50
Barbara McClung	—	—	70
Scott Braunstein	—	—	61
David Johnson	—	—	56
Dara Richardson-Heron	—	—	61
Natalie Sacks	—	—	60
Nancy Whiting	—	—	52
Ran Zheng	—	—	62

Revenue by product and region

Fiscal year ended Dec 31, 2025: $11.16M total revenue

By region

United States$9.48M84.9%
Rest of world$1.68M15.1%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Caribou Biosciences suppliers and customers
Company	Relationship	Country	Correlation
Intellia Therapeutics NTLA	Supplier and customer	US	—
MaxCyte MXCT	Supplier and customer	US	—

Similar companies

Companies in the same industry as Caribou Biosciences

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.